These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 30218317)

  • 1. Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer.
    Houdu B; Lasnon C; Licaj I; Thomas G; Do P; Guizard AV; Desmonts C; Aide N
    Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):421-428. PubMed ID: 30218317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generating harmonized SUV within the EANM EARL accreditation program: software approach versus EARL-compliant reconstruction.
    Lasnon C; Salomon T; Desmonts C; Dô P; Oulkhouir Y; Madelaine J; Aide N
    Ann Nucl Med; 2017 Feb; 31(2):125-134. PubMed ID: 27812791
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Lasnon C; Majdoub M; Lavigne B; Do P; Madelaine J; Visvikis D; Hatt M; Aide N
    Eur J Nucl Med Mol Imaging; 2016 Dec; 43(13):2324-2335. PubMed ID: 27325312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients.
    Lasnon C; Desmonts C; Quak E; Gervais R; Do P; Dubos-Arvis C; Aide N
    Eur J Nucl Med Mol Imaging; 2013 Jul; 40(7):985-96. PubMed ID: 23564036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Harmonizing FDG PET quantification while maintaining optimal lesion detection: prospective multicentre validation in 517 oncology patients.
    Quak E; Le Roux PY; Hofman MS; Robin P; Bourhis D; Callahan J; Binns D; Desmonts C; Salaun PY; Hicks RJ; Aide N
    Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):2072-82. PubMed ID: 26219870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correction to: Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer.
    Houdu B; Lasnon C; Licaj I; Thomas G; Do P; Guizard AV; Desmonts C; Aide N
    Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):533-534. PubMed ID: 30535744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
    Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R
    Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SUV Harmonization Between Different Hybrid PET/CT Systems.
    Rubello D; Colletti PM
    Clin Nucl Med; 2018 Nov; 43(11):811-814. PubMed ID: 30199381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.
    Salavati A; Duan F; Snyder BS; Wei B; Houshmand S; Khiewvan B; Opanowski A; Simone CB; Siegel BA; Machtay M; Alavi A
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1969-1983. PubMed ID: 28689281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variability and Repeatability of Quantitative Uptake Metrics in
    Zhuang M; García DV; Kramer GM; Frings V; Smit EF; Dierckx R; Hoekstra OS; Boellaard R
    J Nucl Med; 2019 May; 60(5):600-607. PubMed ID: 30389824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EANM/EARL FDG-PET/CT accreditation - summary results from the first 200 accredited imaging systems.
    Kaalep A; Sera T; Oyen W; Krause BJ; Chiti A; Liu Y; Boellaard R
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):412-422. PubMed ID: 29192365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does PET Reconstruction Method Affect Deauville Score in Lymphoma Patients?
    Enilorac B; Lasnon C; Nganoa C; Fruchart C; Gac AC; Damaj G; Aide N
    J Nucl Med; 2018 Jul; 59(7):1049-1055. PubMed ID: 29242403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy.
    Zhao K; Wang C; Shi F; Huang Y; Ma L; Li M; Song Y
    BMC Cancer; 2021 Jan; 21(1):66. PubMed ID: 33446134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility of state of the art PET/CT systems performance harmonisation.
    Kaalep A; Sera T; Rijnsdorp S; Yaqub M; Talsma A; Lodge MA; Boellaard R
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1344-1361. PubMed ID: 29500480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the EARL harmonization program on automatic delineation of metabolic active tumour volumes (MATVs).
    Lasnon C; Enilorac B; Popotte H; Aide N
    EJNMMI Res; 2017 Dec; 7(1):30. PubMed ID: 28361349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis of the Role of PET/CT SUVmax in Prognosis and Its Correlation with 
Clinicopathological Characteristics in Resectable Lung Squamous Cell Carcinoma].
    Ren H; Xu W; You J; Song X; Huang H; Zhao N; Ren X; Zhang X
    Zhongguo Fei Ai Za Zhi; 2016 Apr; 19(4):192-9. PubMed ID: 27118646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Total lesion glycolysis by 18F-FDG PET/CT is independent prognostic factor in patients with advanced non-small cell lung cancer.
    Yıldırım F; Yurdakul AS; Özkaya S; Akdemir ÜÖ; Öztürk C
    Clin Respir J; 2017 Sep; 11(5):602-611. PubMed ID: 26434685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How Often Do We Fail to Classify the Treatment Response with [
    Mattoli MV; Calcagni ML; Taralli S; Indovina L; Spottiswoode BS; Giordano A
    Mol Imaging Biol; 2019 Dec; 21(6):1210-1219. PubMed ID: 30850971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EARL compliance and imaging optimisation on the Biograph Vision Quadra PET/CT using phantom and clinical data.
    van Sluis J; van Snick JH; Brouwers AH; Noordzij W; Dierckx RAJO; Borra RJH; Slart RHJA; Lammertsma AA; Glaudemans AWJM; Boellaard R; Tsoumpas C
    Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4652-4660. PubMed ID: 35876867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.